Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.
作者信息
Rubin Eric J, Longo Dan L, Baden Lindsey R
出版信息
N Engl J Med. 2021 Apr 22;384(16):1564-1565. doi: 10.1056/NEJMe2103108. Epub 2021 Feb 25.
Abstract
摘要
相似文献
1
Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.新冠病毒肺炎中白细胞介素-6受体抑制——冷却炎症“汤液”
N Engl J Med. 2021 Apr 22;384(16):1564-1565. doi: 10.1056/NEJMe2103108. Epub 2021 Feb 25.
2
Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.白细胞介素-6受体拮抗剂疗法治疗肾移植受者中由SARS-CoV-2驱动的炎症综合征。
Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5.
3
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.皮下注射托珠单抗阻断白细胞介素-6受体治疗重症新型冠状病毒肺炎及炎症风暴：一项病例对照研究
Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9.
4
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.新冠病毒病危重症患者中的白细胞介素-6受体拮抗剂
N Engl J Med. 2021 Sep 16;385(12):1147. doi: 10.1056/NEJMc2108482. Epub 2021 Aug 18.
5
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply.新冠病毒病危重症患者中的白细胞介素-6受体拮抗剂。回复
N Engl J Med. 2021 Sep 16;385(12):1147-1149. doi: 10.1056/NEJMc2108482. Epub 2021 Aug 18.
6
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply.新型冠状病毒肺炎危重症患者的白细胞介素-6受体拮抗剂。回复
N Engl J Med. 2021 Sep 16;385(12):1149. doi: 10.1056/NEJMc2108482. Epub 2021 Aug 18.
7
IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How?用于新冠病毒病住院患者的白细胞介素-6受体拮抗剂疗法：适用人群、时机及方式？
JAMA. 2021 Aug 10;326(6):483-485. doi: 10.1001/jama.2021.11121.
8
Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia.遗传中介的白细胞介素 6 受体抑制：与 COVID-19 和肺炎的相反关联。
Eur Respir J. 2021 Jan 14;57(1). doi: 10.1183/13993003.03545-2020. Print 2021 Jan.
9
Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 Receptor.针对 SARS-CoV-2 和人白细胞介素-6 受体的细胞因子风暴的赛洛西宾药物衍生物研究。
Front Immunol. 2022 Jan 14;12:794780. doi: 10.3389/fimmu.2021.794780. eCollection 2021.
10
Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.SARS-CoV-2 激活的肥大细胞释放组织胺，增加白细胞介素-1 水平，导致 COVID-19 中的细胞因子风暴和炎症反应。
J Biol Regul Homeost Agents. 2020;34(5):1629-1632. doi: 10.23812/20-2EDIT.
引用本文的文献
1
Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies.新型冠状病毒 2 型的神经精神负担：对其病理生理学、潜在机制及管理策略的综述
Viruses. 2024 Nov 21;16(12):1811. doi: 10.3390/v16121811.
2
Development of a prediction nomogram for IgG levels among asymptomatic or mild patients with COVID-19.COVID-19无症状或轻症患者IgG水平预测列线图的开发
Front Cell Infect Microbiol. 2024 Dec 9;14:1477585. doi: 10.3389/fcimb.2024.1477585. eCollection 2024.
3
The disruptive role of LRG1 on the vasculature and perivascular microenvironment.LRG1对脉管系统和血管周围微环境的破坏作用。
Front Cardiovasc Med. 2024 Apr 30;11:1386177. doi: 10.3389/fcvm.2024.1386177. eCollection 2024.
4
Thyroid tuberculosis and cold abscess after infection with COVID-19: A case report.新型冠状病毒感染后甲状腺结核及冷脓肿：一例报告
Heliyon. 2024 Mar 22;10(7):e28469. doi: 10.1016/j.heliyon.2024.e28469. eCollection 2024 Apr 15.
5
N-glycosylation of the SARS-CoV-2 spike protein at Asn331 and Asn343 is involved in spike-ACE2 binding, virus entry, and regulation of IL-6.SARS-CoV-2 刺突蛋白在 Asn331 和 Asn343 的 N-糖基化参与了刺突-ACE2 结合、病毒进入和 IL-6 的调节。
Microbiol Immunol. 2024 May;68(5):165-178. doi: 10.1111/1348-0421.13121. Epub 2024 Mar 6.
6
Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response.应对新冠疫情后的免疫时代：了解新冠长期症状与免疫反应
Life (Basel). 2023 Oct 26;13(11):2121. doi: 10.3390/life13112121.
7
The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial.托珠单抗和巴瑞替尼联合治疗对重症 COVID-19 病例管理的影响：一项随机开放标签临床试验。
Front Pharmacol. 2023 Oct 19;14:1265541. doi: 10.3389/fphar.2023.1265541. eCollection 2023.
8
The immune-adjunctive potential of recombinant LAB vector expressing murine IFNλ3 (MuIFNλ3) against Type A Influenza Virus (IAV) infection.表达鼠干扰素λ3（MuIFNλ3）的重组乳酸菌载体对甲型流感病毒（IAV）感染的免疫辅助潜力。
Gut Pathog. 2023 Oct 30;15(1):53. doi: 10.1186/s13099-023-00578-5.
9
Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.生长激素释放激素拮抗剂 MIA-602 抑制 SARS-CoV-2 刺突蛋白和细菌脂多糖协同作用在巨噬细胞和人外周血单核细胞中诱导的炎症。
Front Immunol. 2023 Aug 15;14:1231363. doi: 10.3389/fimmu.2023.1231363. eCollection 2023.
10
Quantitative multiorgan proteomics of fatal COVID-19 uncovers tissue-specific effects beyond inflammation.致命性 COVID-19 的多器官定量蛋白质组学研究揭示了炎症之外的组织特异性效应。
EMBO Mol Med. 2023 Sep 11;15(9):e17459. doi: 10.15252/emmm.202317459. Epub 2023 Jul 31.
本文引用的文献
1
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 住院患者中应用秋水仙碱（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet Respir Med. 2021 Dec;9(12):1419-1426. doi: 10.1016/S2213-2600(21)00435-5. Epub 2021 Oct 18.
2
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.托珠单抗治疗重症 COVID-19 肺炎住院患者。
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
3
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
4
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.托珠单抗对重症或危重症 2019 冠状病毒病患者 15 天临床结局的影响：随机对照试验。
BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
5
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
6
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
7
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
8
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
9
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
10
A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.获得性免疫缺陷综合征患者卡氏肺孢子虫肺炎早期使用皮质类固醇辅助治疗的对照试验。加利福尼亚协作治疗组。
N Engl J Med. 1990 Nov 22;323(21):1451-7. doi: 10.1056/NEJM199011223232104.
Zotero 插件